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 29 
Abstract 30 
Auditory neuropathy (AN) is a form of sensorineural deafness specifically affecting the 31 
conduction of the nerve impulse from the cochlear hair cells to the auditory centres of the brain. As 32 
such, the condition is a potential clinical target for ‘cell replacement therapy’, in which a functioning 33 
auditory nerve is regenerated by transplanting an appropriated neural progenitor. 34 
In this review, we survey the current literature and examine possible experimental models for 35 
this condition, with particular reference to their compatibility as suitable hosts for transplantation. 36 
The use of exogenous neurotoxic agents such as ouabain or β-bungarotoxin is discussed, as are 37 
ageing and noise-induced synaptopathy models. Lesioning of the nerve by mechanical damage 38 
during surgery and the neuropathy resulting from infectious diseases may be very relevant clinically, 39 
and we discuss whether there are good models for these situations. We also address genetic models 40 
for AN, examining whether the phenotypes truly model the clinical situation in their human 41 
counterpart syndromes - we use the example of the hyperbilirubinaemic Gunn rat as a particular 42 
instance in this regard.  43 
 44 
 45 
 46 
1. Introduction 47 
The death of the spiral ganglion neuron is a sombre affair. Damage to the auditory nerve may 48 
happen for a number of reasons and can occur as the cause or consequence of hair cell loss - in 49 
either case, the neural lesion is permanent and can be devastating for the patient. In the situation of 50 
profound hair cell loss, the therapeutic option of cochlear implantation is open to some patients, but 51 
this is reliant on there being a degree of neural reserve within the cochlea, so for some this is not a 52 
suitable option. The ability to restock the auditory nerve with a stem cell/progenitor transplant and 53 
restore functionality in patients with auditory neuropathy (AN) would be of significant benefit for 54 
both those with a pure neural lesion and those potential cochlear implant (CI) recipients.  55 
Morphologically, spiral ganglion neurons (SGNs) are bipolar, with a peripheral process 56 
innervating the inner hair cells (IHCs) and a central projection relaying the acoustic stimulus to the 57 
cochlear nucleus in the brainstem. Consequently, any transplanted cells must possess the intrinsic 58 
capacity to ‘rewire’ in both directions, in a host environment which can support this regeneration.  59 
1.1 Scope 60 
The scope of this review will be restricted to the discussion of potential cell therapies for the 61 
neural aspect of sensorineural hearing loss (SNHL). Although significant progress has been made in 62 
the in vitro production of hair cells (Koehler et al., 2017; Li et al., 2003), there still remain several 63 
major technical hurdles to overcome, as current protocols are starkly inefficient at generating 64 
numbers adequate for meaningful hearing restoration. And while it can be argued that highly 65 
differentiated hair cells are not necessary for cell replacement - given that the progenitor population 66 
is the one to be transplanted - the approaches to cell delivery into the scala media and successful 67 
integration of the exogenous cells into the epithelium are as yet in their infancy, with limited 68 
success. It will be a future biological challenge to have cells home and orient correctly within the 69 
exquisitely regimented array of the organ of Corti. 70 
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1.2 Sensorineural pathology in the human ear 71 
Auditory neuropathy (AN) can be described as a complex of conditions affecting neural 72 
output between the cochlea and the brain, specifically when hair cell function is apparently normal 73 
(Starr and Rance, 2015). For example in the audiology clinic, a patient may have a normal distortion 74 
product otoacoustic emission (DPOAE) response, but abnormal auditory brainstem response (ABR) 75 
wave patterns. Determining the site of the underlying dysfunction, for instance whether it lies within 76 
the SGNs and damage to their bipolar processes, is key to understanding the aetiology of the hearing 77 
deficit (Moser and Starr, 2016; Rance and Starr, 2015; Santarelli, 2010). Within AN, a subset of 78 
disorders may be caused by synaptopathy - a degradation of the specialised ribbon synapse at the 79 
level of the IHC. The faithful transmission of the signal between the hair cell and the auditory centres 80 
is necessary for the spatial and temporal integration of incoming sounds; degradation of this 81 
information may be causative factors for age-related and noise-induced hearing loss (Moser and 82 
Starr, 2016) 83 
Detailed and systematic histopathological studies of the damage induced by various causes 84 
to the human cochlea in general, and to the spiral ganglion in particular, are still scarce. However, a 85 
few key papers have explored the underlying pathology in human ears developed as a consequence 86 
of ageing, some genetic conditions and exposure to ototoxic drugs (briefly discussed in Sagers et al. 87 
(2017). A comprehensive study was performed by Makary et al. (2011) reporting the decline of the 88 
spiral ganglion population in the human cochlea induced by ageing. They counted neurons in 100 89 
cochleae from 100 individuals from a broad age range and cases were selected to include only those 90 
with a normal complement of inner or outer hair cells. Neuronal counts declined from a mean of 91 
33679 in the first decade of life, to 22,444 in the tenth decade. This represents approximately a third 92 
of the normal neuronal complement being lost thorough primary degeneration, i.e. not following the 93 
loss of hair cells. Sagers et al. (2017) described the analysis of 30 ears from 23 patients, and showed 94 
that primary neuronal degeneration produced by several different pathologies correlated with the 95 
elevation of auditory thresholds and, more importantly, poor word recognition. Based on their data, 96 
the study developed a model that predicts that mean hearing thresholds are increased by 6.0dB for 97 
each 10% of neurons lost. 98 
Progress in the transplantation field has been steady, with a few groups showing cell 99 
integration and functional restoration in ‘deafened’ animal models - but are these models a good 100 
facsimile of the clinical situation? It is likely that an initial good model for transplantation should 101 
have a near total loss of the host’s SGNs, so that any restored function or innervation can be 102 
attributed with confidence to the transplanted cells. However, given the partial loss seen in some 103 
human conditions, it will be good in the future to develop a subtler approach with a graded deficit, 104 
which might replicate some of the clinical situations more accurately. 105 
This review will cover some of the animal models available currently, with an analysis of 106 
which are, in our opinion, the most appropriate for these studies, at this stage.  107 
 108 
2. Ototoxic lesions of the auditory nerve 109 
2.1 β-Bungarotoxin 110 
β-bungarotoxin is a potent neurotoxin isolated from the venom of the krait family of snakes. 111 
Its activity is manifold, and it can paralyse the neuromuscular junction by transiently increasing and 112 
then blocking acetylcholine release. It is also lethal in the central nervous system – in vitro studies 113 
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have elucidated how it kills hippocampal neurons by the binding to and internalisation of voltage-114 
gated potassium channels, leading to an increase in intracellular calcium ions and reactive oxygen 115 
species generation, resulting in apoptosis (Herkert et al., 2001; Shakhman et al., 2003). 116 
As an ototoxic agent, it may have application through its more selective actions on neurons 117 
rather than hair cells – in the developing chick embryo, application of the toxin gave rise to a loss of 118 
afferent and efferent nerve fibres in the basilar papilla and saccular macula and a degeneration in 119 
the neurons of the acoustic-vestibular ganglion, in the context of developmentally normal hair cells 120 
(Hirokawa, 1977). In mammalian studies, β-bungarotoxin has been use to de-innervate mouse 121 
cochlea explants in vitro (Corrales et al., 2006) and to de-afferent the rat cochlea in vivo prior to 122 
stem cell transplants (Jiao et al., 2014; Palmgren et al., 2010; 2012). However, direct application of β-123 
bungarotoxin to the rat round window niche using gelfoam, led to substantial increments of the ABR 124 
thresholds with no immediately evident spiral ganglion loss. A significant death of SGNs was only 125 
detectable 3 weeks post intervention. This time window between intervention and cellular damage 126 
would suggest that the effect is indirect and, although hair cells are preserved, other structures 127 
could have been affected such as the stria vascularis. This may limit the use of this model for a 128 
targeted reparative strategy to the spiral ganglion 129 
Furthermore, when we modified these protocols and applied them to the gerbil, mixed results 130 
were achieved. Local application of β-bungarotoxin to the gerbil round window membrane (RWM) 131 
on a gelfoam plug showed no evidence of threshold shift, when concentrations comparable to those 132 
used in previously published work were used. At a higher concentration though, a substantial raising 133 
of the ABR threshold to a click stimulus could be attained within a few days of treatment, with a 134 
concomitant loss of Type I SGNs found by immunofluorescence after 5 weeks (Fig.1F, H, N, P) 135 
compared with the untreated condition (Fig.1B, D, J, L). Both the Type II SGNs (Fig. 1E, H) and the 136 
hair cells (Fig. 1M, P) were unaffected by the treatment. However, in order to achieve this neural 137 
loss, the toxin concentration had to be increased to a level whereby unpalatable ‘off-target’ effects 138 
such as hind-limb paresis and urinary incontinence were evident, prompting the termination of 139 
these experiments for welfare reasons. The potential for intra- and extra-cochlear off-target effects 140 
would lead to it being a less than ideal candidate for use as a neuropathy-inducing agent, particularly 141 
since it was no more effective than ouabain (see section 2.5, below).  142 
2.2 Pyridoxine 143 
Pyridoxine, or Vitamin B6 in common parlance, has been associated with the onset of toxic 144 
sensory neuropathy in patients consuming high daily doses (van Hunsel et al., 2018), and has been 145 
employed as a neuropathological agent in animal models (Umapathi and Chaudhry, (2005) and 146 
references therein). There are limited reports of pyridoxine’s use as a specific agent to target 147 
auditory neurons. Hong et al. (2009) showed that daily systemic injections of the compound at 175, 148 
350 or 700mg/kg gave a dose-dependent threshold shift of up to 60dB for both click and 8kHz tone 149 
stimuli. Interestingly, the onset of the deficit was around 5 weeks after the initiation of the 150 
treatment and gradually worsened until the experiments ceased at 10 weeks; the histology of the 151 
auditory nerve showed atrophy of the nerve fibres and thinning of their myelin sheaths. Notably, off-152 
target effects such as the ataxia seen in rat pyridoxine models (Perry et al., 2004) were absent in 153 
these mice, save for a mild effect on the tail flick latency. There may also be an outer hair cell (OHC) 154 
loss associated with this pathology, shown by a loss of otoacoustic emission (OAE) signals arising 8 155 
weeks after the onset of treatment – however this loss could be ameliorated by the neuroprotective 156 
effects of trigonellone or freeze-dried coffee, implying that the hair cell loss may arise as a secondary 157 
consequence of SGN deterioration rather than a primary insult by the pyridoxine (Hong et al., 2009). 158 
Further work is required to shade in the details of these intriguing findings - as such, this may prove 159 
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a good model for a slow and chronic neuropathy, as opposed to the rapid and catastrophic neural 160 
loss found with other agents.  161 
2.3 Sodium salicylate 162 
Transient SNHL and tinnitus have been well characterised as side effects of high doses of sodium 163 
salicylate, the active ingredient in aspirin. There is a breadth of data suggesting that salicylate has 164 
pleotropic effects on the hearing system – it is posited that salicylate-induced upregulation of the 165 
electromotility protein prestin in the OHCs may lead to their overactivity. The consequent imbalance 166 
with IHC firing may lead then lead to the perception of tinnitus, which itself may be exacerbated by 167 
salicylate’s central effects on GABAergic and serotonergic activity in auditory areas of the brain 168 
(Sheppard et al., 2014). There is, however, conflicting evidence from in vitro and in vivo studies to 169 
suggest that chronic salicylate exposure may lead to a selective and permanent loss of SGNs via 170 
superoxide-mediated apoptosis. In organotypic cultures from young rat pups, Deng et al. (2013) saw 171 
a salicylate-mediated SGN loss which spared the adjacent hair cells and support cells; their in vivo 172 
experiments showed that chronic exposure led to a decrease in the compound action potential 173 
(CAP) measured at the round window (RW) (Sheppard et al., 2014). However, the I/O function 174 
produced indicated that the OHCs were functioning normally and the anomaly lay with the discharge 175 
from damaged SGNs. Conversely in the guinea pig, Feng and co-workers (2011a; 2011b) saw an 176 
upregulation of caspase-mediated apoptosis in both hair cells and SGNs after chronic salicylate 177 
administration.  178 
So, although salicylate intoxication of the cochlea may represent a physiological model in terms 179 
of a ‘real world’ situation, it may not give a ‘clean’ neuropathy model. Thus, it may be difficult to 180 
interpret the results of a neural cell transplant in the potential context of concomitant hair cell 181 
damage and altered cortical activity.  182 
2.4 Glutamatergic excitotoxicity 183 
Excessive stimulation of the afferent dendrites by glutamate (or some of its analogues such as 184 
kainic acid) can lead to the loss of SGNs and may be the pathological process bringing about the 185 
damage caused by cochlear ischaemia, age related hearing loss with underlying vascular atrophy 186 
(Pujol et al., 1990) and even sepsis (Schmutzhard et al., 2013). The excitotoxic loss is worst in SGNs 187 
with low spontaneous discharge rates (‘low-SR’ fibres) and high sound thresholds (Furman et al., 188 
2013) and so could lead to impaired speech comprehension, which may be particularly relevant in 189 
patients presenting with so-called ‘hidden hearing loss’ (HHL) caused by cochlear synaptopathy. 190 
For many years, signalling at the afferent post-synaptic density remained opaque. The most 191 
established view is that afferent neurotransmission between the IHCs and the SGNs is 192 
predominantly mediated by AMPA receptors (Takago and Oshima-Takago, 2018). However, using a 193 
combination of RT-PCR and immunohistochemistry, Peppi et al. (2012) suggested that the 5 kainate 194 
receptor subunits (GluK1-5) were localised to the post-synaptic density of the afferent fibres, where 195 
they were coexpressed with AMPA receptors - this receptor mix may be underlying the transmission 196 
of the signal from the IHCs. This localisation was further refined by Fujikawa et al. (2014), who 197 
showed that GluK2 and GluK5 were present at the post-synaptic side of the afferent cleft, with, 198 
intriguingly, GluK2 also being present on the IHC, suggesting that the recycling of glutamate may be 199 
occurring on both sides of the synapse.  200 
Overstimulation of the cochlea with kainic acid has been used as a model for glutamatergic 201 
damage. Although at lower doses, the loss of neural responses has been found to be reversible in 202 
the guinea pig (Sakai et al., 2008) and chinchilla (Zheng et al., 1997; Zheng et al., 1999), an increased 203 
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dose has been shown to lead to a 34% loss in Type I SGNs in the rat (Juiz et al., 1989). Using the 204 
different components of the ABR wave complex as a metric for the health of different aspects of 205 
auditory neural transmission, Henry and Abrams (2018) found that kainate intoxication caused a 206 
persistent reduction in wave i amplitude in the budgerigar, implying a selective damage or 207 
synaptopathy had occurred at the level of the auditory nerve. The differing susceptibility of the SGNs 208 
may reflect current thinking as to the heterogeneity of the sensory afferent population (Petitpre et 209 
al., 2018; Shrestha et al., 2018). There may be species-differences in the susceptibility of the hair 210 
cells to excitotoxic damage. For instance, in the rat, the hair cells were unscathed by the kainate 211 
insult (Juiz et al., 1989) but in the gerbil, the glutamate agonist AMPA was found to induce IHC death 212 
at high concentrations (Hyodo et al., 2009).  213 
There is potential in the use of kainic acid or other glutamatergic agonists as a method of 214 
inducing AN - if the dose can be titrated correctly, it may give a clean loss of neurons, or more 215 
intriguingly, the loss of a subset of neurons, which may have implications for the treatment of 216 
cochlear synaptopathy-based HHL. 217 
 218 
2.5 Ouabain 219 
Ouabain is derived from Stropanthus gratus, a member of the liana family, whose leaves and 220 
seeds have been used for both traditional medicine and arrow poison in many African countries. 221 
Latterly, it has been adopted in Western medicine as an agent for the treatment of hypotension and 222 
cardiac issues (Whayne, 2018). It acts by inhibiting the α subunit of the Na
+
, K
+
-ATPase pump (NKA); 223 
NKA is a ubiquitous heterotrimeric enzyme consisting of catalytic α and β subunits and a regulatory γ 224 
subunit which work together to move sodium and potassium ions across cell membranes against 225 
their concentration gradient using ATP as an energy source. The different α subunits (ATP1A1-4) 226 
have varying sensitivities to ouabain, with α3 being more strongly inhibited than α2, and α1 being 227 
the least affected by the drug. ATP1A3 is particularly abundant in neurons, particularly throughout 228 
the peripheral processes and somata of the Type I SGNs (Delprat et al., 2007; McLean et al., 2009), 229 
whereas ATP1A2 is expressed by glia and ATP1A1 has a broad distribution. The topical application of 230 
ouabain to the RWM can be used as a tool to induce cell death in the spiral ganglion neurons 231 
without damaging the organ of Corti - this is advantageous as a model for cellular transplantation, as 232 
it preserves the putative trophic support given by the hair cells and support cells to the grafted 233 
progenitors. 234 
The use of ouabain as a neurotoxic agent has been widespread in the field. Early work 235 
demonstrated the effects of ouabain on the endocochlear potential by direct infusion of the drug 236 
into the perilymph of the guinea pig (Konishi and Mendelsohn, 1970) or application at the RW in the 237 
chinchilla (Rybak et al., 1984), brought about by its actions on the stria vascularis. However, these 238 
effects were transient and almost completely absent in the gerbil (Schmiedt et al., 2002). Ouabain’s 239 
use as neuropathy-inducing agent was therefore pioneered in the gerbil (Lang et al., 2005; Matsuoka 240 
et al., 2007; Schmiedt et al., 2002) where it has been shown to induce apoptosis of Type I SGNs 241 
within a few hours post-application, leading to robust obliteration of this cell type by 4-8d post-242 
treatment. This provides an ideal backdrop for cell transplantation studies (Chen et al., 2012; 243 
Matsuoka et al., 2007). The mechanism of cell death being induced has been a matter of debate, 244 
with the term ‘necroptosis’ being coined. Cultured cortical neurons begin by swelling transiently in 245 
response to ouabain treatment, similar to neurons undergoing an excitotoxic lesion (see section 2.4), 246 
followed by intracellular Ca
2+
 build-up and a K
+
 efflux which triggers cell shrinkage characteristic of 247 
necrosis and caspase activation leading to apoptosis (Xiao et al., 2002); these processes are thought 248 
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to occur concurrently within single cells, leading to a ‘hybrid death’ phenotype. In vivo, this process 249 
may be triggered by ouabain-mediated upregulation of Receptor Interacting Protein 3 (Rip3), a 250 
necroptosis pathway activator - Wang et al. (2014) showed that the ~50dB ABR threshold shift 251 
induced in the rat by 10mM ouabain could be prevented by the concurrent application of apoptosis 252 
and necroptosis inhibitors. This may have implications clinically for acute ototoxic incidents, with 253 
there being scope for the prevention of cell death with such drugs. Intriguingly, Type II SGNs are 254 
spared and do not die after ouabain treatment, and there remains debate as to why this should be 255 
the case. A simple explanation would be that they do not express ATP1A3 (McLean et al., 2009) and 256 
so are relatively ouabain resistant, due to their expression of a less-sensitive subunit. However, their 257 
perdurance even after exposure to high concentrations of the drug (Chen et al., 2012; Lang et al., 258 
2005) suggests that they may be more efficient at invoking protective mechanisms - the toxic influx 259 
of Ca
2+
 caused by ouabain might be being buffered by the higher levels of calcineurin present in the 260 
Type II SGNs compared to the Type I (Lang et al., 2005), and so the necroptosis pathways remain 261 
untriggered. 262 
Indeed, the use of low doses (10-100µM) in the gerbil gives a gradation of fibre loss which 263 
may be a relevant clinical model for synaptopathy-based HHL, wherein a patient’s pure tone 264 
audiogram may be normal but speech becomes unintelligible to them in a noisy environment. 265 
Bourien (2014) and Huet and co-workers (2018) demonstrated in the gerbil that a 33µM dose of 266 
ouabain led to the loss of low-SR nerve fibres which did not affect the CAP threshold or amplitude, 267 
but which could lead to a reduced discriminatory ability in noisy circumstances. Increasing this dose 268 
to 66µM again did not alter the CAP threshold, but did reduce its amplitude due to the loss of 269 
medium- and high-SR fibres and a loss of synchrony in the response onset. Similar work in the mouse 270 
(Parthasarathy and Kujawa, 2018; Yuan et al., 2014) set out to titrate the ouabain treatment to give 271 
differing degrees of deafferentation and look at the effects on synaptic density and auditory 272 
responses. A loss of presynaptic ribbons and a decrease in the post-synaptic density at the IHCs was 273 
found, alongside tantalising evidence of neural plasticity - abnormal giant terminals were also seen 274 
in aberrant locations on the IHC, indicative of a neural remodelling which has failed to associate 275 
correctly with the hair cell ribbon synapses. Concomitantly, a raising of ABR thresholds was found, 276 
but only once a substantial number (>80%) of synapses had been lost. Thus, by using ouabain at 277 
these lower doses, there may be scope for uncovering the subtleties of the progressive loss of 278 
synapses, fibres and cell bodies which may be causative for the AN phenotype. 279 
The concept of ‘central compensation’ can also be addressed with ouabain treatment. In 280 
some intricate and elegant experiments, Chambers and co-workers (2016a; 2016b) have 281 
demonstrated the plasticity of central processing after an auditory lesion. In mice treated with 1mM 282 
ouabain, the ABR and acoustic startle responses were both eliminated, but a behavioural paradigm 283 
for tone detection still gave a positive response, even in animals who had lost >90% of their 284 
synapses. Incredibly, activity in the auditory centres of the brain was maintained: in the inferior 285 
colliculus and the auditory cortex, activity recovers during the month following the lesion, and in 286 
some cases is more robust than in control animals. An explanation for this finding could be that the 287 
basic features of sound, encoded by variations in spike rate, can be reinstated and that the central 288 
gain on signals from the peripheral afferents can be increased to compensate for erosion of this 289 
input. These higher-level, hyperexcitable circuits might amplify signals which are too weak to be 290 
picked up in the form of an ABR in the brainstem. Thus, ouabain might provide a good model for the 291 
over-reaction of central systems thought to underlie the tinnitus and hyperacusis comorbidities 292 
sometimes found with AN. 293 
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It is important to consider the condition of the cochlea post-ouabain, particularly if the 294 
onward goal is cell transplantation. The inflammatory response post-ouabain in the mouse has been 295 
carefully characterised, revealing a recruitment of macrophages after a 3mM treatment (Brown et 296 
al., 2017) which are seen to engulf the dying SGNs and an upregulation of haematopoietic stem cell 297 
homing factors (Noble et al., 2018). There also must be consideration of the effect on the resident 298 
glial population - a 200µM dose in vitro (Xiao et al., 2002) does not affect glia. It has been reported 299 
that 3mM ouabain can trigger proliferation of the resident Schwann cell population in the mouse 300 
cochlea with an increase in BrdU
+
/Sox10
+
 cells. There is also an upregulation of neurogenesis 301 
markers such as GFAP and nestin in these cells, suggesting that the glia of the injured nerve may 302 
possess neural stem cell-like properties (2011; 2015). There may be, however, some discrepancies 303 
over this result - Zhang et al. (2017) applied this same 3mM dose in the same mouse strain and saw 304 
a loss of S100+ Schwann cells; and in our lab, we see a loss of these cells in both mouse and gerbil 305 
with a 5mM dosing regimen (Mallick et al., manuscript in preparation). 306 
Despite its widespread usage, there has been a wide variation in the literature as to the 307 
dosage and treatment regimens - ‘application at the RWM’ seems to have a range of interpretations 308 
- and so, there are somewhat mixed results, which may also reflect anatomical differences between 309 
species, alongside differential drug sensitivities. In the guinea pig, some workers have shown that 310 
comparatively little damage was done to the SGNs after RW application in spite of spiral ligament, 311 
stria vascularis and OHC damage being present (Hamada and Kimura, 1999), whereas others have 312 
observed diverse and unpredictable responses with no damage to the stria and variable SGN 313 
damage (Schomann et al., 2018). Results from ouabain treatment in the rat suggest that its toxic 314 
phenotype may lie somewhere between that of the gerbil and the guinea pig - a basal to apical 315 
gradient in the severity of SGN loss was found, with a substantial loss of both IHCs and OHCs (Fu et 316 
al., 2012). Suggestions have been made to explain these disparities, with a likely explanation being 317 
the underlying anatomy of the species in question. For example, the modiolus of the gerbil cochlea is 318 
closer to the RWM than that of the guinea pig or rat (Chamberlain, 1977; Schmiedt et al., 2002) and 319 
so there may be more direct access for the drug to intoxicate the neurons. Additionally, there may 320 
be an effect between different experimenters - numerous, short applications of the drug may give 321 
rise to a more severe and consistent toxic phenotype than a single incubation, since the steepness of 322 
the concentration gradient is repeatedly replenished. 323 
The clinical relevance of ouabain application as a model for human hearing loss conditions 324 
may extend beyond selective fibre loss and synaptopathies. There have been reports of patients 325 
with mutations in ATP1A3 presenting with CAPOS syndrome (cerebellar ataxia, areflexia, pes cavus, 326 
optic atrophy and SNHL) (Demos et al., 2014; Han et al., 2017). More recently, the hearing loss has 327 
been revealed as a form of AN, with normal OAEs but abnormal ABRs indicative of a neural 328 
dyssynchrony (Tranebjaerg et al., 2018), suggesting that ouabain application may be a good model 329 
for the deafness aspect of this rare condition. 330 
 331 
3. Mechanical lesions of the auditory nerve 332 
In chemically-lesioned AN models (e.g. by the application of ouabain), the primary insult 333 
occurs at the level of the soma or the peripheral processes of the spiral ganglion fibres. But in 334 
surgical situations, for instance when a patient undergoes the excision of an acoustic neuroma via a 335 
retro-sigmoidal approach, the VIIIth nerve can be damaged within its more central portion, beyond 336 
the internal auditory meatus. Earlier studies by Spoendlin and Suter (1975; 1976) described some 337 
intriguing results after resection of the auditory nerve in the cat and the guinea pig. He observed a 338 
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gradual loss of the Type I fibres which began in the basal turn and progressed over the course of 339 
several months; after two years however, the majority of SGNs had been lost and only the Type II 340 
neurons perdured - their resilience, also observed after ouabain damage to the peripheral processes, 341 
is surely worthy of note. This cut lesion model also showed evidence of neural regeneration - 342 
Spoendlin described the presence of ‘giant’ fibre endings packed with mitochondria which form 343 
some form of synapse at the IHC, and remarkably this phenomenon endured for nearly two years 344 
post-lesion. Alas, the data trail for this potential recovery from such central-process lesions went 345 
cold for over two decades until Sekiya, Ito and co-workers published a series of papers elucidating a 346 
method for generating an alternative auditory nerve injury model to the central axonal processes. By 347 
gently crushing the nerve at the level of the internal auditory meatus in the rat, they could induce a 348 
progressive, apoptotic loss of Type I SGNs whereby the extent of damage could be titrated according 349 
to the speed and depth of compression (Sekiya et al., 2000; Sekiya et al., 2003). Again, the 350 
extraordinary resistance of the Type II neurons to this damage was noted - even after 8 months, they 351 
remained intact, as did the hair cells (Matsumoto et al., 2008). However, there was a reduction in 352 
cell numbers centrally in the posterior ventral cochlear nucleus and the dorsal cochlear nucleus 353 
(Sekiya et al., 2009) implying an anterograde degeneration progressing centrally as well as the 354 
retrograde losses in the cochlea itself. Critically however, this lesioning spared the internal auditory 355 
artery - a key factor in this model, since loss of blood supply to the cochlea is known to result in 356 
complete fibrosis of the organ within a couple of weeks (Sekiya et al., 2000). 357 
The response of the glia to the crush injury is a key feature of this model which may lend it 358 
clinical relevance. In patients undergoing surgery to remove tumours from this area, there is often a 359 
delayed hearing loss observed - on waking, their hearing seems to have been preserved, only to 360 
degrade over the subsequent couple of months. This degeneration may correlate with the amount 361 
of mechanical trauma the auditory nerve receives during the course of the surgery (Sekiya et al., 362 
2011). In the rat model, after 8 weeks a dense, gliotic ‘scar’ had formed, spanning the lesion and 363 
extending beyond the Obersteiner-Redlich zone into the peripheral cochlear nerve. However, the 364 
overgrowth of these GFAP- positive, astrocytic fibres has the potential to be a blessing in disguise. 365 
Although this scar tissue may squeeze the life from any remaining auditory nerve fibres (Sekiya et al., 366 
2011) and is  generally considered to inhibit the growth of neural fibres, it could be induced to act as 367 
a scaffold for a cell transplant. It may have the potential to bridge any gaps and give a route along 368 
which cells can migrate into the periphery of the cochlea (Sekiya et al., 2006; Sekiya et al., 2015). The 369 
crush lesion also recruits a large influx of macrophages at the compression site and it was found that 370 
treatment of injured animals with methylprednisolone could reduce this inflammatory response and 371 
protect the SGNs (Sekiya et al., 2001). Thus, steroid treatment may provide an effective therapeutic 372 
avenue for hearing preservation in patients undergoing, for instance, vestibular Schwannoma 373 
surgery. 374 
 375 
4. Ischaemia 376 
Ischaemia induces swelling of the afferent dendrites beneath the IHCs, in a mechanism 377 
thought to be mediated by glutamate (see section 2.4 above, regarding the similarities of this with 378 
excitotoxic damage). A loss of blood flow to the cochlea rapidly starves its cells of ATP, and this 379 
energy depletion leads to a drop in the endocochlear potential (Tabuchi et al., 2010). This causes 380 
glutamate to build up in the synaptic cleft and accrue in the perilymph as it is no longer taken up 381 
correctly by cells, via transporters such as GLAST, with the effect of a loss of ionic homeostasis and 382 
water and ion influx into the dendritic processes of the afferents. However, as catastrophic as this 383 
may seem at initial examination, the synapse is remarkably plastic and, if the episode of anoxia is 384 
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brief (5 minutes or shorter), then there is repair of dendrite and the hearing loss is transient. If there 385 
is a prolonged period of starvation though, the damage becomes irreversible, leading to cell 386 
blebbing and eventual death. This may require some finessing to be used as a cell transplantation 387 
model, as there is evidence of a hair cell loss in conjunction with SGN losses after an ischaemic 388 
incident, as found in the guinea pig by Lin and coworkers (Lin et al., 2010). Although in the gerbil, 389 
there is contradictory evidence regarding whether the damage occurs mostly at the level of the hair 390 
cells rather than the SGNs after transient ligation of the vertebral arteries (Okada et al., 2013; 391 
Taniguchi et al., 2002; Watanabe et al., 2009; Yoshida et al., 2007) - the outcome may depend on the 392 
duration of the anoxia. 393 
 394 
5. Metabolic causes of neuropathy 395 
5.1 Diabetes 396 
An under-reported but impactful consequence of Type 1 and Type 2 diabetes mellitus is the 397 
increased prevalence of hearing loss amongst patients (Bainbridge et al., 2008) and, with the global 398 
increase in diabetes and pre-diabetic conditions, this is likely to become a significant contributing 399 
factor in adding to the deafness burden world-wide. The aetiology of this hearing loss is currently 400 
unclear, with speculation based on other, hyperglycaemic consequences that the microvasculature 401 
of the cochlea may be affected, with consequences for the stria vascularis and maintenance of the 402 
endolymph. Chronically-raised blood glucose levels also leads to oxidative stress, microglial 403 
activation and neuropathy (Helzner and Contrera, 2016) and there are strong indications of 404 
degeneration in the peripheral auditory fibres (Bainbridge et al., 2008). ABR testing in Type 1 405 
patients revealed changes in the latency of waves i, iii and iv (Mujica-Mota et al. (2018) and 406 
references therein); and, in the limited histology data from diabetic patients, degenerative changes 407 
in the SGNs have been observed, amongst other pathologies (Makishima and Tanaka, 1971). Animal 408 
models for these conditions are known to have hearing pathologies as part of their phenotypic 409 
spectrum - for instance, the Zucker Diabetic Fatty rat has a moderate increase in ABR thresholds 410 
(Meyer zum Gottesberge et al., 2015) - and there is evidence for AN in the mouse model of Type 1 411 
diabetes (Hong and Kang, 2008). The condition can be induced by a single injection of streptozotocin 412 
(STZ) and animals show aberrant ABR responses when tested 4-10 weeks later, with raised click 413 
thresholds and altered inter-peak latencies, with the severity of the delay being directly related to 414 
the initial dose of STZ (Hong and Kang, 2008; 2014; Hong et al., 2008). Thus, this model may be 415 
useful for examining AN with differing severity levels; information is, as yet, lacking regarding the 416 
histology of the cochlea in these animals and it will be key for taking this important model forward. 417 
5.2 Neonatal jaundice 418 
Neonatal jaundice is a risk factor for damage within the auditory system. It arises due to 419 
elevated levels of bilirubin in the bloodstream, for example because of the high levels of red blood 420 
cell turnover in the newborn, and leads to a characteristic yellowing of the skin. Although common, 421 
particularly in pre-term infants, it is usually self-limiting, requiring minimal intervention for 422 
successful resolution. However, in cases with an early and rapid onset (less than 24 hours post 423 
partum) or with a prolonged duration (2-3 weeks of symptoms), this severe jaundice may reflect an 424 
underlying metabolic issue and become pathological, resulting in kernicterus (bilirubin 425 
encephalopathy) - babies are left with lasting and often severe neurological damage, not least of 426 
which is an auditory phenotype (Ramachandran, 2016). Lesions are thought to occur in the cochlear 427 
nucleus, the superior olive and the lateral lemniscus amongst other components of the central 428 
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auditory processing pathway - Perlman et al. (1983) showed a variety of disruptions to the ABR 429 
waves measured from jaundiced babies. There is some controversial evidence for the existence of 430 
peripheral lesions, with reports of high frequency hearing loss and ‘word aphasia’, which could be 431 
indicative of a cochlear synaptopathy condition (Shapiro and Nakamura, 2001). Despite the 432 
therapeutic options available, neonatal jaundice remains a leading cause of neurodevelopmental 433 
disorders, particularly in developing nations, with the financial and societal costs that accompany 434 
the care of neurodisability (Amin et al., 2017). 435 
Modelling neonatal hyperbilirubinaemia in animals has been approached in a number of 436 
ways. The injection of bilirubin alone is adequate to induce mild auditory damage in the guinea pig 437 
(Ye et al., 2012) and rat (Gokdogan et al., 2016). However, in order to model the more severe 438 
damage seen in affected children, accompanying the bilirubin with sulphonamide-based compounds 439 
such as sulfadimethoxine (‘sulfa’) has been an effective strategy in mice (Schiavon et al., 2018), rats 440 
(Karplus et al., 1988) and Rhesus monkeys (Ahlfors et al., 1986). These sulphonamides outcompete 441 
bilirubin for serum albumin binding sites, causing it to be displaced and to leach out into tissues 442 
where it causes damage by inducing neuroinflammation and triggering intracellular stress 443 
mechanisms (Schiavon et al., 2018). In addition, hyperbilirubinaemia may occur as a secondary 444 
consequence of haemolytic disease in the newborn - the impaired recycling of red blood cells causes 445 
both iron and bilirubin levels to rise, with associated neurotoxic consequences. To model this 446 
condition, the drug phenylhydrazine (PHZ) has been used to exacerbate haemolysis in young rats (Li 447 
et al., 2014; Mejia et al., 2008). This causes an increase in circulating bilirubin levels and thereby 448 
induces a transient auditory impairment in young rats (Li et al., 2014) with a longer-lasting loss of 449 
Neurofilament-200 immunoreactivity in the SGNs. Coupled with the apparent sparing of the hair 450 
cells, this model warrants further investigation as a potential candidate for neural progenitor 451 
transplant. As might be expected, the PHZ-induced damage can be exacerbated by co-injection with 452 
sulfa (Amini et al., 2017). 453 
The Gunn rat (Gunn, 1938) is a spontaneously-arising animal model for Crigler-Najjar type 1 454 
syndrome, a recessive familial metabolic disorder in which a deficiency in the uridine-diphosphate-455 
glucuronosyl transferase A1 (UDP-GT1A1) enzyme prevents the conjugation of bilirubin to 456 
glucuronide in the liver. Consequently, bilirubin cannot be excreted as normal in the bile and 457 
accumulates at toxic levels in the bloodstream – the lipid solubility of this unconjugated bilirubin 458 
facilitates its transfer across the blood-brain barrier and its subsequent deposition in brain tissue, 459 
causing kernicterus. Rats carrying the jj genotype are phenotypically similar to affected human 460 
patients, displaying a pronounced jaundice (Fig 2A, B) - pups can be identified with 100% confidence 461 
on the basis of their skin colouration prior to confirmation by genotyping. They may also display 462 
neurological deficits such as ataxia – rats display a pronounced ‘wobble’ when walking (Chaniary et 463 
al. (2009) and our unpublished observations), cerebellar hypoplasia (Fig. 2C and Conlee and Shapiro 464 
(1997)) and mild hearing loss. A similar phenotype is seen when the UGT1 locus is targeted in the 465 
mouse (Bortolussi et al., 2012; Nguyen et al., 2008; Ronzitti et al., 2016). 466 
However, the Gunn mutation in isolation may not give rise to an adequate auditory 467 
dysfunction as a result of the bilirubin-induced neurotoxicity – for instance, mild aberrations in the 468 
latency of certain components of the ABR wave complex were found (Shapiro and Hecox, 1988; Uziel 469 
et al., 1983), whereas other workers found no deficit in the jj mutants (Levi et al., 1981). There was 470 
also evidence of normal ECoch recordings and an intact organ of Corti (Uziel et al., 1983). 471 
Consequently, it has become routine to enhance the phenotype either by inducing haemolysis to 472 
increase circulating bilirubin with phenylhydrazine (Rice and Shapiro, 2008) or, more commonly, by 473 
injecting affected animals with sulphonamide-based compounds such as sulfasoxisole (Blanc and 474 
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Johnson, 1959) or ‘sulfa’ (Schutta and Johnson, 1969), which cause the circulating bilirubin to leach 475 
out into the tissues. Sulfa injections produce a more severe form of the ABR latency irregularities 476 
seen in untreated jj animals, ranging from interwave latency anomalies through to an absence of 477 
waves i to iv (Shapiro, 1993; Shapiro and Hecox, 1988; Shapiro and Conlee, 1991) and for many 478 
years, these effects were assumed to be a problem intrinsic to central auditory processing deficits – 479 
sulfa injections were seen to result in significant reductions in cell size in the medial nucleus of the 480 
trapezoid body (MNTB), alongside a reduction in the volume of the cochlear nucleus which was 481 
directly correlated to the amplitudes of the different wave components of the ABRs in those animals 482 
(Conlee and Shapiro, 1991; Shapiro and Conlee, 1991). Evidence of a failure of synaptic transmission 483 
at the glutamatergic Calyx of Held terminals in the MNTB was demonstrated in some very elegant 484 
experiments where degeneration of the excitatory presynapse was shown by multi-photon imaging 485 
(Haustein et al., 2010). However, hints at a peripheral lesion in the cochlea itself or in the auditory 486 
nerve were shown by the diminution of wave i in the ABRs of sulfa treated animals (Shapiro and 487 
Conlee, 1991) and evidence of damage to the SGNs was shown by Shaia et al. (2005). Three days 488 
after being injected with sulfa, the SGNs appeared shrunken and demyelinated compared to saline-489 
injected controls, accompanied by axonal degeneration in the central portion of the nerve but in the 490 
context of good preservation of both inner and OHCs. There is a preferential loss of large-diameter 491 
axons, which may underlie the temporal dyssynchrony observed in both these animals and in 492 
patients diagnosed with AN. 493 
This animal would, in theory, represent an ideal candidate for a neuropathy/transplantation 494 
model, since it loses the neuronal reserve but spares the mechanotransduction machinery. The 495 
Gunn rat has already been used as a transplant model for other aspects of its pathology. Animals 496 
have undergone liver transplants with hepatocytes derived from human neonatal livers (Tolosa et 497 
al., 2015) or induced hepatocytes derived from reprogrammed human skin fibroblasts (Chen et al., 498 
2015), and in both reports, long term correction of the enzymatic defect and a lowering of serum 499 
bilirubin levels was achieved. There have also been shorter-term studies looking at the potential of 500 
human neural progenitor transplants to repair the kernicterus-induced damage in the brains of jj 501 
animals, with the intriguing observation that the raised levels of bilirubin may actually act as an anti-502 
inflammatory and immunosuppressive agent, protecting the transplanted cells from the host’s 503 
immune system (Yang et al., 2018; Yang et al., 2017). 504 
We have directed our attention to the use of the Gunn rat as a host for human otic neural 505 
progenitor (hONP) transplants, as a parallel model to the ouabain paradigm we currently employ. 506 
However, despite our best efforts, the results in our hands were disappointing. We took two 507 
approaches for the development of a neuropathy model - namely, the investigation of the 508 
phenotype in older animals to see if a long-term neurotoxicity would arise from a lifetime of high 509 
serum bilirubin levels and a repeat of the sulfa administration experiments in young pups to assess 510 
the resultant auditory phenotype (Fig. 3). The results on both accounts were unexpected. Firstly, an 511 
aged cohort of Jj (n=7) and jj rats (n=10) ranging from 6 to 18 months of age were tested in our 512 
standard ABR paradigm. There was no shift in ABR threshold for the click (Jj - 28dB SPl, jj - 27.6dB 513 
SPl; Fig. 3A) or pure tone (Fig. 3C) protocols. There was no reduction in the amplitude of wave ii-iii in 514 
the click ABR complex (Fig. 3B) at any of the measured sound intensities, or in any of the individual 515 
peak latencies (data not shown) for the jj animals compared with their Jj siblings, implying that 516 
neural conduction along the auditory pathway is occurring normally. When serum bilirubin levels 517 
were measured using the ultramicromethod (Walters and Gerarde, 1970), the jj animals were found 518 
to have an average serum bilirubin level of 8.15mg/dl (n=11 animals, range of 3.21 to 13.14mg/dl) 519 
compared to 0.21mg/dl in their Jj relatives (n=7 animals, range of 0.01 to 0.4mg/dl), confirming a 520 
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lifelong bilirubinaemia. Injecting jj pups with sulfadimethoxine at early ages had no effect on the 521 
auditory system when ABRs were measured 4-6 weeks later - auditory thresholds were not 522 
significantly different in sulfa-treated animals compared with saline-treated sibs at the click (saline - 523 
20.8dB SPl, sulfa - 23.2dB SPl; Fig. 3D) or tone (Fig. 3F) levels, with no change in wave ii-iii amplitude 524 
(Fig. 3E) or peak latencies (data not shown). Both injected cohorts were hyperbilirubinaemic, with 525 
levels of 5.9mg/dl in saline treated jj animals (n=9, range 4.66mg/dl to 8.96mg/dl). In neither the 526 
aged jj cohort nor the sulfa-injected jj animals did we see a significant reduction of spiral ganglion 527 
neurons - when we compare this with the rapid and catastrophic neural loss we achieve with 528 
ouabain (Chen et al., 2012), it becomes apparent that, currently, the Gunn rat is not an appropriate 529 
model for ONP transplantation.  530 
Notwithstanding the apparent lack of a neuronal phenotype, the Gunn rat proved difficult as 531 
a consistent model for neuropathy and transplantation in our experience. There was a marked 532 
difference in the life outcomes for jj mutant pups. Mutant homozygotes broadly fell into two 533 
populations, being either nominally healthy (notwithstanding their tendency to being underweight 534 
compared with siblings, see Gunn (1944) for the first description of this), or moribund - this is in 535 
marked contrast to the six-point clinical rating scale described by Spencer et al. (2002). Pups, 536 
particularly from larger litters would fail to thrive and enter a vicious downward spiral from around 537 
P10 to weaning age, at around 3-4 weeks (also described by Graham et al. (1980). They would 538 
become irritable, hyperactive (Stanford et al., 2015) and hypervocal (Lenhardt, 1982) followed by a 539 
descent into lethargy. A lack of feeding, either due a failure of the pups to navigate to the mother or 540 
by active maternal neglect (Cahalan and Graham, 1978), would result in dehydration which is 541 
thought to enhance transfer of bilirubin across the blood-brain-barrier (Bratlid et al., 1983).Despite 542 
the best attempts at supportive therapies with fluid replacement, nutritional supplementation and 543 
the use of activated charcoal or calcium phosphate chews to reduce serum bilirubin levels (Davis et 544 
al., 1983; Van Der Veere et al., 1996) there was an inexorable slide into further neural deterioration 545 
and animals would require euthanasia. Our experience with the colony mirrored that described by 546 
both Gunn (1944) and Johnson et al. (1959), in which a substantial proportion of jj pups were lost, 547 
whilst the survivors remained remarkably unscathed. This bimodal phenotypic distribution may 548 
underline the importance of the contribution of the genetic background to the expressivity of the 549 
condition, similar to the results seen by Stobie et al. (1991), who saw a four-fold increase in jj pup 550 
mortality when the mutation was carried on the ACI genetic background as opposed to the RHA 551 
background. Indeed, these observations mirror those of Bortolussi et al. (2014) who saw a marked 552 
difference in survival of UGT1
-/-
 mouse pups depending on the background strain harbouring the 553 
mutation. After a couple of generations in our facility, it was discovered that our Gunn colony was 554 
not an inbred line, as initially thought, with the appearance of albino progeny from Agouti ‘hooded’ 555 
parents arising from outcrossing of the colony at their previous institution - the effect of modifiers 556 
within the genetic background should not be taken for granted and may well have been influencing 557 
the Gunn phenotype.  558 
An unexpected consequence of the Gunn phenotype was also revealed in animals surviving 559 
in the longer term. At the age of 6-9 months and beyond, animals developed haematuria, with post 560 
mortem examination revealing scarring and cystic lesions on the kidneys. There is little evidence of 561 
this in the Gunn rat literature - Martinez-Maldonado et al. (1969) and Call and Tisher (1975) both 562 
address a urinary concentrating defect which may be due to crystalline bilirubin affecting kidney 563 
function; and bilirubin-induced nephropathy was described by Odell et al. (1967) – but it is clearly a 564 
problem in terms of keeping animals for a longer procedural duration, particularly since transplanted 565 
animals would require immunosuppression using drugs which may cause additional nephrotoxicity 566 
(Whiting and Simpson, 1983).  567 
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 568 
6. Genetic models  569 
Having a genetically inducible, ‘clean’ model of AN, in which the hearing loss is purely at the 570 
level of the neurons without the added complication of hair cell involvement, would be a boon for 571 
hearing researchers. It is known that human patients carrying mutations in genes expressed in the 572 
SGNs or auditory nerve have worse outcomes after cochlear implantation. For example, pathogenic 573 
variants of TMPRSS3, a gene of unknown function, lead to a profound deafness with normal cochlear 574 
microphonics but reduced auditory nerve activity and therefore poorer results in implanted patients 575 
(Shearer et al., 2018). 576 
A few reports exist describing mouse mutants, in which the criteria of SGN 577 
degeneration/loss without apparent effects on the hair cells are fulfilled. The saposinB knock-out 578 
mouse models a slow and progressive demyelination and ultimate loss of the SGNs, triggered by a 579 
primary loss of the satellite cells cosseting the sensory afferent fibres, whilst the efferent system and 580 
hair cells are preserved intact (Akil et al., 2015). The deafness in these animals becomes apparent 581 
from 6 months old, which is roughly equivalent to 30 years of age in humans; thus these mice may 582 
effectively mirror the inexorable hearing loss experienced by many of us with advancing age - 583 
although, to be used as a neuroprogenitor transplant host, it may require the grafting of a bi-potent 584 
cell population which have the capacity to differentiate as both SGNs and Schwann cells.  585 
Demyelination of the auditory nerve is thought to contribute to AN, particularly where 586 
neural dyssynchrony may be occurring (Long et al., 2018). To this end, there have been reports of 587 
mouse models which may model this problem. In the Trembler
J
 mouse, peripheral demyelination of 588 
the auditory nerve is predicted to underlie the latency and wave i amplitude anomalies seen in the 589 
ABR traces; a similar but less severe phenotype was seen in mice harbouring a conditional disruption 590 
of the Schwann cells (Zhou et al., 1995a; Zhou et al., 1995b). A targeted and specific reduction of the 591 
SGNs with diphtheria toxin (Pan et al., 2017) did not alter ABR thresholds in the recipient mice, but 592 
dramatically reduced the amplitude of the CAP response. Alongside a significant drop in the 593 
numbers of SGNs post-treatment, there was also evidence of degenerative pathology in terms of the 594 
thickness of the myelin sheath, albeit with the caveat that this may have occurred as a secondary 595 
consequence of the neural intoxication. 596 
Intriguingly, there is evidence that demyelination may be causative for some forms of HHL 597 
(Kohrman et al., 2019). In a mouse model where the cochlear Schwann cells were genetically 598 
ablated, the resulting transient loss in myelination of the SGNs resulted in a permanent drop in the 599 
amplitude of wave i of the ABR complex at suprathreshold sound intensities, in the absence of any 600 
synaptic loss (Wan and Corfas, 2017). Rather, persistent damage was observed at the first 601 
heminodes of the SGNs, implying that the propagation of the neural response was being affected. 602 
This may underlie the anomalous hearing phenotypes found in patients with demyelinating 603 
neuropathy conditions such as Guillain-Barré syndrome or Charcot-Marie-Tooth disease (Kohrman et 604 
al., 2019; Rance and Starr, 2015). 605 
There is also scope for the further characterisation of the auditory neural phenotype in 606 
mouse models of diseases known to cause neuropathy in patients. For example, the mitochondrial 607 
disease Friedrich’s ataxia causes SNHL in many patients, with dyssynchrony in AN firing patterns 608 
(Santarelli et al., 2015): mouse models of this condition are known to recapitulate many of the 609 
disease symptoms, but the physiology or histology of the auditory system has not yet been 610 
described (Chandran et al., 2017). As a caveat to relying too heavily on extrapolation between 611 
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species however, in the dominant mitochondrial condition optic atrophy 1 (Opa1), human patients 612 
have no activity in the auditory nerve in spite of apparently normal hair cell function (Huang et al., 613 
2009), whereas the mouse model shows normal hearing (Davies et al., 2007).  614 
On the other hand, some genetic models of AN, whilst being invaluable for their contribution 615 
to our knowledge of exactly how the cochlea functions, may not be currently suitable as models for 616 
cell transplantation. For example, the otoferlin mouse mutants model the autosomal recessive 617 
human DFNB9 condition, in which a profound, prelingual deafness with the hallmarks of AN arise 618 
(Pangrsic et al., 2010; Roux et al., 2006). However, the lesion affects the replenishment of vesicles at 619 
the IHC ribbon synapse; consequently, the deafness phenotype would not necessarily be improved 620 
by a neural progenitor transplant replacing the SGNs. In the case of bone remodelling disorders such 621 
as Paget’s disease, there is often an accompanying hearing loss (Amilibia Cabeza et al., 2018). A 622 
mouse knockout for the osteoprotegerin protein models such a condition (Kao et al., 2013), and 623 
there is clear evidence for a substantial degeneration of the SGNs in these animals which does not 624 
affect the hair cells, so this could be, in theory, a target for transplantation - however, the 625 
confounding effects of the conductive loss also found in this model could hinder the physiological 626 
assessment of any recovery.  627 
Menière’s disease (MD) is a complex and debilitating disorder characterised by 628 
endolymphatic hydrops and, in many cases, a fluctuating hearing loss. There is a wealth of literature 629 
and much debate in the field regarding the underlying pathology and this is largely beyond the scope 630 
of this review. However, the Phex mouse mutant may be a useful adjunct to the canon of MD 631 
research (Semaan et al., 2013). A mutation in the X-linked phosphate regulating gene (Phex) 632 
produces, amongst other bone-related abnormalities, endolymphatic hydrops. Moreover, there is a 633 
progressive loss of SGNs in an apical to basal gradient, which recapitulates the degenerative pattern 634 
seen in patients; the hair cells are preserved until advanced stages and it would be interesting to see 635 
if they could be preserved with an early progenitor transplant. 636 
 637 
7. Noise-Induced Hearing Loss (NIHL) 638 
A scourge of modern-day living is the constant bombardment of noise, at levels of exposure 639 
never previously experienced in human history - traffic, machinery, the ubiquitous ‘ear bud’ piping 640 
music into the external auditory meatus - all of these add up to contribute to increasing levels of 641 
hearing impairment, increasingly amongst younger adults. Permanent damage due to noise-induced 642 
hearing loss (NIHL) is brought about by pathological levels of sound which blast through the hair 643 
cells, ripping away the stereociliary bundle. However, a more insidious, pervasive damage is thought 644 
to underlie the concept of the ‘temporary threshold shift’ - noise which causes a steep increase in 645 
ABR threshold, which rapidly and subsequently returns to normal. The landmark study by Kujawa 646 
and Liberman (2009) laid the groundwork for the creation of animal models of NIHL, with careful 647 
titration of the noise ‘dose’ in order to maximally damage the ANFs without harming the hair cells, 648 
save for a little damage to the OHCs in the ‘hook’ region at the extreme base of the cochlea. The 649 
work demonstrated that although ABR thresholds remained normal, there was a reduction in wave i 650 
amplitude, specifically in the same tonotopic regions corresponding to the toxic noise frequencies. 651 
Examination of the synapses showed a degradation of the contacts between the IHCs and the ANFs; 652 
in subsequent studies, refinements in staining techniques showed that both the pre- (using CtBP2) 653 
and post-synaptic (using Glu2/3 or PSD-95) densities were affected and for a comprehensive 654 
overview of the work in this field, the reader is pointed to the review of Hickox and Whitton (Hickox 655 
et al., 2017). The synaptic loss then leads to a slow degeneration of the SGNs, caused by a gradual 656 
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retraction of the afferent fibres and death of the cell bodies, possibly due to a loss of trophic support 657 
from the organ of Corti. Indeed, in mice where the ErbB-neuregulin signalling axis has been 658 
disrupted by the expression of a dominant negative ErbB receptor in the supporting cells of the 659 
organ of Corti, the SGNs loss their trophic support and die back, due to an apparent drop in 660 
neurotrophin (NT-3) expression, demonstrating the critical feedback and support mechanisms the 661 
SGNs rely upon for their health (Stankovic et al., 2004). 662 
Close examination of the electrophysiological aspects of the synaptopathic phenotype using 663 
single unit recordings uncovered again a particular vulnerability to damage in the low-SR fibres in the 664 
guinea pig (Furman et al., 2013) and mouse (Liberman et al., 2015), somewhat akin to their peculiar 665 
sensitivity to ouabain (see section 2.5). The loss of these high-threshold fibres has been proposed to 666 
underlie the phenomenon of cochlear synaptopathy described above. When levels of ambient noise 667 
increase, the hypothesis is that the low-SR fibres are pressed into action on account of their large 668 
dynamic range and their relative insensitivity to noise masking. However, there is considerable 669 
recent controversy regarding the relevance of these animal models. In a cohort of human patients 670 
with known ‘speech in noise’ deficits, there was no correlation with (albeit self-reported) noise 671 
exposure. Moreover, no anomalies were found during electrophysiological testing - ABR wave i 672 
amplitude was normal (if anything, with a trend to be slightly higher than in ‘normal’ hearing 673 
controls) and there was no alteration in the wave i-v ratio (Guest et al., 2018). There is currently 674 
little evidence in humans that low-SR fibres have high response thresholds or that synaptopathy 675 
leads to perceptual consequences. There may be so many other confounding effects in human sound 676 
processing that while animal models are of use for understanding the cellular and biochemical 677 
mechanisms of sound intoxication, they may be limited for deeper perceptual interpretation. 678 
There is an intriguing finding in animals exposed to low level noise (LLN), equivalent in human terms 679 
to working in a relatively noisy, but not superficially ‘pathogenic’, environment. This degree of noise 680 
exposure is enough to give temporary shifts in ABR threshold, which return to normal when the LLN 681 
ceases with apparently no damage to the SGNs or hair cells. However, Frye et al. (2018) showed that 682 
there was an infiltration of macrophages which took two months to return to normal; it is tempting 683 
to speculate what harm this could lead to in the longer term, with repeated exposure. Indeed, an 684 
increase in inflammatory mediators by glia and the neurons themselves, alongside leukocyte 685 
recruitment post-noise exposure could represent an amenable target for therapeutic intervention to 686 
prevent noise-induced damage (Arslan et al. (2017); Fuentes-Santamaria et al. (2017); Tan et al. 687 
(2013) and references therein). 688 
8. Ageing 689 
One of the seemingly inevitable consequences of the march of time is our decreased ability 690 
to hear that clock ticking. By the age of 65, half of us will suffer from some degree of age-related 691 
hearing loss (ARHL), and with the advances in public health and medicine which have so dramatically 692 
increased our lifespan, we are still trying to understand how to improve this aspect of our 693 
healthspan. 694 
For many years, the dogma seemed to be that the cumulative daily insults we expose our 695 
hair cells to would ultimately lead to their dysfunction and death, with the subsequent die-back of 696 
the SGNs as they lost support from the organ of Corti. There is a change in thought about this direct 697 
pathway though, based on information from different animal models and also the recognition of 698 
cochlear synaptopathy-mediated HHL in older adults (see section 7, above), where hair cell function 699 
is clinically normal but neural responses are affected under certain acoustic conditions. There may 700 
exist a selection of differing pathologies resulting from independent degeneration of the hair cells, 701 
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SGNs or stria vascularis; there is also some evidence that degeneration of the fibrocytes of the spiral 702 
limbus may be the primary insult resulting in neural loss, particularly in the apical region of the 703 
cochlea (Ohlemiller and Gagnon, 2004). The value of an animal neuropathy model for ageing must lie 704 
in its ability to recapitulate the pathology seen in human patients. As explained in the introduction, 705 
this becomes a Gordian knot in hearing research, due to the paucity of post-mortem human samples 706 
and the conflicting range of lesions which have been documented in these tissues. Counts from 707 
cochlear samples from the over-60s showed a 30-40% loss of OHCs, but with a greater than 60% loss 708 
of SGNs in the majority of cases - meanwhile, the IHCs were mostly intact (Wu et al., 2018). This SGN 709 
loss is slower than in most comparable animal models, and there is also the phenomenon of ‘neuritic 710 
presbycusis’, in which the peripheral fibres of the SGNs are lost, but the cell bodies survive. This 711 
could be a therapeutic window of opportunity for repair – work by Suzuki et al. (2016) has shown in 712 
the noise-induced model that it may be possible to regrow these peripheral fibres and re-establish 713 
synapsis by the judicious application of neurotrophic factors such as NT3 or BDNF. At the very least, 714 
the protection afforded by these factors may stall any further damage and allow for greater success 715 
in CI patients (Landry et al., 2011; 2013). 716 
The ageing human neuropathy has a parallel with the ouabain neuropathy model (see 717 
section 2.5 above) - in both the ageing human and the intoxicated animal cochlea, the Type II SGNs 718 
remain steadfast and persist. Perhaps herein lies the secret to neural survival; if we could install the 719 
Type II afferents’ protective mechanisms across the afferent population, we may be to stop neural 720 
degeneration in its tracks. Current advances in genomics have shed light on the different ‘flavours’ of 721 
SGNs and so a deeper analysis of these datasets may shed light on these key differences (Petitpre et 722 
al., 2018; Shrestha et al., 2018). 723 
Whereas a model for an age-related pure neuropathy still requires work, there is a 724 
substantial body of work on the synaptopathy aspect of ageing, and its relationship with noise 725 
exposure. Experiments with mice experiencing noise at young ages showed a deterioration of neural 726 
responses and SGN degeneration in old age compared to noise-naïve animals of the same age 727 
(Kujawa and Liberman, 2006), implying that the sublethal changes introduced by this early noise 728 
exposure made the cochlea more vulnerable to age-related damage. A single dose of synaptopathic 729 
noise early in life could accelerate the loss of synapses in older age, spreading out along to the 730 
cochlea to encompass even regions which were not initially covered by the pathological noise 731 
frequency band (Fernandez et al., 2015; Kujawa and Liberman, 2015). There is also a tendency to 732 
lose the low-SR synaptic contacts as a result of noise exposure, so maybe carefully-titred noise 733 
lesions will be an appropriate facsimile for the human condition, where temporal degradation of the 734 
neural signal and a diminishing of hearing acuity could be a sequela of low-SR loss (Kujawa and 735 
Liberman, 2015; Parthasarathy and Kujawa, 2018). 736 
Modelling the synaptic loss in the ageing mouse using a machine learning approach may give 737 
us an invaluable tool to take to the clinic. By populating their model with wave i ABR amplitudes and 738 
DPOAE responses, Bramhall et al. (2018) were able to predict the number of remaining synapses in 739 
mice aged between 1 month and over 2 years to an astonishing degree of accuracy, confirming their 740 
computational results with immunofluorescence for synaptic, hair cell and afferent fibre markers. 741 
Using this model in a clinical setting could be a revolutionary tool - being able to accurately predict 742 
the benefit a patient would receive from a given prosthesis would save the heartache of crushed 743 
hopes and be of significant gain from a healthcare economics perspective. 744 
There are genetic conditions whereby the clinical manifestations of hearing loss appear to 745 
mimic ARHL but on a more accelerated timescale - in patients carrying mitochondrial (mtDNA) 746 
mutations, the phenotypic spectrum of the resulting syndrome can often encompass progressive 747 
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deafness similar to that seen in ARHL. By creating a ‘mutator’ mouse strain with a progressive 748 
accumulation of mtDNA lesions, Niu et al. (2007) demonstrated how the resultant mutations 749 
resulted in a progressive hearing loss with an apoptotic degeneration of both peripheral and central 750 
auditory neurons which spared the IHCs, alongside a loss of neural density centrally in the cochlear 751 
nucleus. When comparing the ABR profiles of the 10 month old ‘mutator’ mice with 2 year old wild-752 
types of the same strain, there was a similar and profound raising of the hearing threshold, the 753 
suggestion being that the mutator mice were showing an accelerated presbyacusis phenotype. This 754 
mouse strain could be of great benefit to the field of ARHL because it may develop the relevant 755 
phenotypes without the attendant financial and ethical considerations of maintaining an ageing 756 
mouse colony. 757 
Despite many years of research, the mechanisms underlying ARHL, largely remain opaque. 758 
There are, however, some interesting hints that the symbiotic relationship between the SGNs and 759 
their glia (Wang et al., 2009). Mice were generated carrying a conditional knock-out of two of the 760 
fibroblast growth factor receptors (FGFR1 and FGFR2), specifically affecting the peripheral Schwann 761 
cells and central oligodendrocytes of the auditory nerve. These animals displayed a late-onset and 762 
progressive loss of hearing, the underlying pathology of which was a ‘pure’ neuropathy: animals had 763 
a significant (ca. 50%) loss of SGNs across all three cochlear turns without any losses in the hair cells 764 
or mutant glia. The authors proposed a breakdown in the reciprocal signalling arrangement between 765 
the SGNs and the glia: in the normal situation, they hypothesised that FGF secreted by said neurons 766 
activates FGF-responsive pathways in the glia, which respond by secreting the neurotrophins the 767 
SGNs need for support. Consequently, there could be a protective role for FGF in neuropathy 768 
models, both in ageing and acute situations.  769 
ARHL is likely to be a multifactorial problem, with a number of contributing features such as 770 
ageing, genetics, and environmental influences e.g. exposure to chemicals or noise pathologies.  771 
 772 
9. Infectious diseases 773 
9.1 Viruses 774 
Many viral diseases are known to result sensorineural deafness, either by a direct cytotoxic 775 
effect on cochlear tissues, or by secondary damage caused by inflammation. For some viral 776 
infections e.g. herpes simplex virus, the damage is thought to occur in the stria vascularis or the 777 
organ of Corti and so discussion of these conditions is outwith the scope of this review. 778 
Advances in public health have led to a reduced incidence in these viral causes of deafness, 779 
particularly in developed nations - for instance, mass vaccination for measles, mumps and rubella in 780 
the U.K. has almost eliminated post-infection deafness for the former two diseases and greatly 781 
reduced cases of congenital rubella syndrome in infants. In some cases, anti-viral therapies have 782 
helped with the outcomes for infected patients - for example, treatment with ganciclovir can halt 783 
the progression of cytomegalovirus (CMV)-induced SNHL (Cohen et al., 2014). However, CMV still 784 
remains an unfortunate burden when untreated or in its asymptomatic form: it has a high incidence, 785 
occurring in 0.2-0.5% of live births, of whom 10% will go on to develop hearing loss, accounting 786 
overall for a quarter of childhood deafness cases (Usami et al., 2017). The virus causes a wide variety 787 
of hearing loss phenotypes, which may be profound, asymmetric, and, in some cases, progressive 788 
with a delayed onset which may occur up to 16 years of age (Riga et al., 2018). As may be expected, 789 
there is debate regarding the underlying pathology, with an understandably limited amount of post-790 
mortem tissue available for examination; there is evidence of damage to the stria vascularis and 791 
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supporting cells with an infiltration of inflammatory cells around both infected and non-infected 792 
cells (Teissier et al., 2011). 793 
Modelling CMV infection in vivo has proved difficult, with conflicting opinions as to the 794 
optimal method of infection (intra-cerebral or intra-peritoneal?) and differing patterns of damage 795 
seen in the mouse and guinea pig (Bradford et al., 2015; Carraro et al., 2017; Li et al., 2015; Schraff 796 
et al., 2007; Tian et al., 2015; Wang et al., 2013; White et al., 2006). Perhaps of use as an AN model 797 
would be the neonatal intra-peritoneal injection model used by Bradford et al. (2015) - 6 weeks 798 
post-infection, infected mice had raised ABR thresholds, in some instances with unilateral and/or 799 
fluctuating hearing loss, thus mirroring the phenotypic spectrum of human patients. Histological 800 
examination showed infection, followed by a substantial loss, of the SGNs, accompanied by an 801 
infiltration of CD3+ cells and an upregulation of proinflammatory cytokines. Indeed, a prolonged 802 
inflammatory insult with high levels of IL-6, TNFα, ROS and the activation of the ‘inflammasome’ 803 
(Schachtele et al., 2011; Zhuang et al., 2018) may bring about the demise of the SGNs as a secondary 804 
insult rather than the primary viral infection itself, and this may be comparable to the macrophage 805 
infiltration found in the spiral ganglion region after ouabain intoxication (Brown et al., 2017). 806 
Lassa fever is a haemorrhagic virus with over 500,000 cases diagnosed annually, mainly in 807 
West Africa. When considering that one third of surviving patients develop SNHL during the latter 808 
stages of their infection or during convalescence (Mateer et al., 2018), there is a considerable long-809 
term healthcare and socio-economic burden from this neglected disease. A lack of biopsy or post-810 
mortem specimens entails that currently, the aetiology of the deafness is as yet unclassified. 811 
Developing a mouse model for this disease has proved challenging - somewhat unsurprisingly, there 812 
is a very high attrition rate in animals when they are infected with a virulent human strain (Yun et al., 813 
2015). However, when a milder variant is used, the animals develop SNHL 1-2 months after the 814 
initial infection - similar to the human situation - with degeneration of the SGNs which spares the 815 
vast majority of the hair cells. Notwithstanding the regulatory difficulties of working with human 816 
pathogens, there is scope for exciting research with this model, as it may fulfil the criteria for being a 817 
‘pure’ AN model - it would be interesting to observe the CAP and ABR measurements over time and 818 
in the presence of ribavirin, the anti-viral therapy for Lassa infections. There is again an influx of 819 
CD3+ lymphocytes into the auditory nerve tissue, which may be a unifying feature when considering 820 
models of auditory nerve damage - perhaps one is intrinsic to the other. 821 
 822 
9.2 Bacterial infections 823 
Although recurrent bacterial infections in the middle ear cleft (known as ‘glue ear’ or otitis 824 
media) can result in deafness, this is usually a conductive loss brought about by fusion of the middle 825 
ear bones - rarely, there may be damage to the auditory nerve accompanying this, giving a ‘mixed’ 826 
hearing loss. Nevertheless, there are bacterial diseases which can result in AN. Hearing loss is one of 827 
the most common complications of bacterial meningitis, with nearly 10% of patients being left with 828 
some degree of deafness due to hair cell or auditory nerve damage from the bacteria themselves, 829 
the exotoxins they produce, or the immune response mounted to the infection (Perny et al., 2016). 830 
Henceforth, an animal model for this infection is important for the understanding of the underlying 831 
pathological mechanisms. In an infant rat model of Streptococcus pneumoniae infection, a dose-832 
dependent hearing loss was observed - the higher the initial bacterial inoculum, the greater the shift 833 
in hearing thresholds, with the focus of damage being in the basal turn. This was also reflected in the 834 
degree of SGN loss, which was more substantial in high frequency rather than low frequency regions. 835 
The OHCs were severely affected too, but whilst the IHCs remained unscathed superficially, an 836 
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investigation of the remaining afferent synapses revealed a significant loss of presynaptic ribbons. 837 
Consequently, this model may be good for recapitulating the post-meningitic sensory deficits, and be 838 
of use for investigating drug-based interventions to prevent such damage. Interestingly, there was a 839 
positive correlation between the increase in threshold with the level of TNFα in the cerebrospinal 840 
fluid - still more evidence that the immune system may play both the role of superhero and 841 
supervillain in the cochlea. At the moment, however, this model has some limitations for its use in 842 
neural cell transplantation studies. The severe damage suffered by the hair cells (primarily the OHCs) 843 
would be a barrier to measure functional recovery. Moreover, the health of the central pathway has 844 
not yet been properly explored; it is likely that it would also be compromised given the 845 
administration of the bacterial inoculum into the cisterna magna.  846 
 847 
10. Concluding remarks 848 
In summary, the causes leading to the loss of SGNs in humans and experimental animals are 849 
multiple, and the underlying physiopathogenic mechanisms are better understood in some 850 
conditions than in others. However, and as mentioned in the introduction, an ideal model to study 851 
cell replacement of the cochlear neurons by cell transplantation should have a phenotype that is 852 
robust, reproducible and, ideally, affects mostly the SGNs preserving, at least partially, other cell 853 
types.  854 
We believe that the ouabain model has been reasonably well characterised and offers an 855 
appropriate framework from which to develop a cell-based strategy. In our own experience, it is far 856 
more reproducible and robust than other models we have explored, such as the β-bungarotoxin 857 
application or the Gunn rat. Reproducibility and the limited ability to accurately control the extent of 858 
the damage are still the limitations of the subtler, graded models. Future studies will, hopefully, 859 
develop even better model systems that could be used to further advance cell therapy technologies 860 
in the ear. 861 
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 867 
Figure legends 868 
 869 
Fig. 1 – Effects of 0.5µM β-bungarotoxin application to RWM, 5 weeks post-treatment. There is a loss 870 
of Type I SGNs in the treated (E-H; M-P) vs. the untreated ear (A-D, I-L), as shown by the drastic 871 
reduction in βIII-TUBULIN positive cells (green cells in F, N; compared to B, J). There is preservation 872 
of Type II neurons shown by the perdurance of PERIPHERIN positive cells (arrowheads, A, E). The 873 
continued presence of MYOSIN7A in the treated ear (M) compared with the untreated (I) shows that 874 
both inner (*) and outer ([) hair cells are unharmed by the treatment (I, M). 875 
 876 
Fig. 2 - Gunn rat phenotypes. Gunn rat pups are obvious by d7 due to their yellow colouration (A, jj) 877 
compared to their pink heterozygous siblings (A, Jj). Adults retain a yellow tinge to their ears, paws 878 
and tail (B - ‘Archie’ - 18 month old homozygous male), and have a smaller cerebellum (cb) (jj vs. Jj in 879 
C). Some animals also develop kidney lesions (D) - the organ becomes misshapen and may have 880 
urine-filled cysts (arrow, D). Genotyping the animals is simple and based on a RFLP - the Gunn 881 
mutant allele loses an MvaI site. PCR products from genomic DNA covering this region are digested 882 
and the resulting fragments are visualised by standard agarose gel electrophoresis (E), allowing Jj 883 
hets and jj homs to be identified. Differences in serum bilirubin levels (F) are obvious in all jj animals; 884 
quantification of this in pre- and post-weaning (ca.22-28d) animals shows this to be highly 885 
statistically significant (one-way ANOVA, p<0.0001). Mean bilirubin levels were 0.81mg/dl for 886 
heterozygous pups (n=12), compared to 17.34mg/dl for their homozygous siblings (n=20); and 887 
0.23mg/dl for adult heterozygotes (n=31) vs. 10.54mg/dl for adult homozygotes (n=26). 888 
 889 
Fig. 3 - Comparison of auditory responses in aged het (Jj; age range 8-18 months, n=7) vs. hom (jj; 890 
age range 6-18 months, n=10) animals (A-C) and hom pups injected with saline (n=9) or sulfa (n=9) 891 
and assayed 4-6 weeks post exposure (D-F). There is no significant difference in ABR click threshold 892 
in aged jj mutant animals compared to Jj hets (A), nor is there any alteration in the wave ii-iii 893 
complex amplitude (B). Pure tone thresholds are statistically similar at all tested frequencies (C; 2-894 
32kHz). Similarly, sulfa injections have no effect in the longer term - click thresholds (D), wave ii-iii 895 
complex amplitude (E) and pure tone thresholds (F) are all unaffected in jj animals treated with sulfa 896 
compared to those injected with saline. 897 
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Highlights 
 
• This article reviews the current available animal models that could potentially be used to 
study stem cell transplantation to treat auditory neuropathy 
• We discuss a range of etiologies and species, covering ototoxic and metabolic damage, 
mechanical trauma and ischemia, infectious agents, genetics, noise-induced damage and 
aging. 
• A critical assessment is provided of our current understanding of the pathogenesis 
behind the models, their relevance to human clinical conditions and their potential 
application for cell therapy studies. 
 
 
 
